SAB Biotherapeutics, Inc. (SABSW) cash flow statement

SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 4/30

$0.01+0.00 (+33.33%)

Close on Oct 20, 2026Market cap $304.80MP/E –Yield –

SAB Biotherapeutics, Inc. cash flow statement

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31
Depreciation & Amortization	2.97	2.97	2.99	3.02	3.22	3.42	4.71	4.79	4.89	4.79	3.65	3.70	3.59	3.44	3.17	2.90	2.38	1.88	1.49
Stock-Based Compensation	17	10	5.21	2.71	2.96	2.94	2.94	2.80	2.40	2.44	2.42	2.52	2.45	2.38	2.67	2.70	3.00	2.86	2.31
Change in Accounts Receivable	–	–	–	–	–	–	–	–	–	–	5.56	13	9.25	11	2.45	-2.73	7.50	-0.19	13
Change in Accounts Payable	1.45	0.91	1.48	1.75	1.55	1.36	0.92	0.23	-0.23	-0.22	-2.70	-4.40	-3.54	-3.54	-0.78	1.36	-0.57	1.42	-2.94
Change in Unearned Revenue	–	–	–	–	–	–	-1.32	-1.51	-2.78	-2.56	1.32	1.63	2.89	2.94	-0.10	–	–	–	–
Operating Cash Flow	-54	-51	-45	-38	-31	-31	-34	-38	-37	-34	-25	-13	-16	-16	-23	-27	-15	-17	1.99
Capital Expenditures	–	–	–	–	–	–	-0.34	-0.35	-0.33	-0.30	-0.20	-0.25	-0.24	-0.83	-2.17	-4.41	-7.56	-10	-11
Sale of Property, Plant & Equipment	0.00	0.00	0.00	–	–	–	–	–	–	–	0.04	0.04	0	0	0.08	–	–	–	–
Purchase of Investments	-294	-281	-142	-131	-6.23	-6.29	-37	–	–	–	–	–	–	–	–	–	–	–	–
Sale & Maturity of Investments	96	91	21	21	24	–	26	–	–	–	–	–	–	–	–	–	–	–	–
Investing Cash Flow	-202	-192	-122	-111	18	24	-12	-21	-20	-31	-0.15	-0.20	-0.24	-0.83	-2.09	-4.33	-7.48	-10	-11
Stock Issued	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0
Taxes Paid on Share-Based Awards	-0.02	-0.01	-0.01	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Financing Cash Flow	261	258	168	169	-0.81	-0.95	-1.17	66	67	67	67	7.52	7.38	7.01	1.05	29	29	30	36
Foreign Exchange Rate Adjustments	-0.31	-0.24	-0.21	-0.10	-0.02	-0.17	-0.24	–	–	–	–	–	–	–	–	–	–	–	–
Net Change in Cash	4.58	15	1.60	20	-14	-8.39	-48	6.75	9.47	0.97	42	-5.91	-8.84	-9.35	-24	-2.42	6.38	2.28	27
Free Cash Flow	–	–	–	–	–	–	-35	-39	-37	-35	-25	-13	-16	-16	-26	-31	-23	-27	-8.96
Interest Paid	0.23	0.24	0.24	0.25	0.36	0.38	0.37	0.37	0.27	0.23	0.25	0.33	0.27	0.30	0.29	0.21	0.29	0.29	0.29

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 15.0%

Financial strength

Current ratio: 9.22
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 70.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.42
Dividend yield: –